TD Cowen initiated coverage of Freenome with a Buy rating and a $17 price target, citing differentiated liquid biopsy chemistry and commercial partnership momentum with Abbott and Roche. The analyst’s model points to sales ramp driven by Freenome’s multi-cancer early detection (MCED) and lung cancer-related assays, with uptake tied to its CRC test SimpleScreen CRC. The coverage highlights a strategy of using cash flow from commercial partnerships to reinvest into additional blood-based screening assays. It also flags risks including high cash burn, projected capital needs, and limited visibility into pipeline timelines. For biotech markets, the note reflects how financial analysts are now treating liquid biopsy platforms as platform businesses with interdependent test commercial performance.